Osteoporosis & Menopausal Disorders-SMi Conference.
Foley
Patrick
P
Thomson Current Drugs, London, UK. patrick.foley@current-drugs.com
D056657:Cathepsin K; D002403:Cathepsins / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control*; D010446:Peptide Fragments / Q000627:therapeutic use; D048789:Phytoestrogens; D028321:Plant Preparations / Q000627:therapeutic use; D044169:Receptors, Calcium-Sensing / Q000037:antagonists & inhibitors; D014807:Vitamin D / Q000031:analogs & derivatives / Q000627:therapeutic use
D007529:Isoflavones; D010446:Peptide Fragments; D048789:Phytoestrogens; D028321:Plant Preparations; D044169:Receptors, Calcium-Sensing; D014807:Vitamin D; D002403:Cathepsins; C534130:CTSK protein, human; D056657:Cathepsin K